Uses of DPP IV inhibitors

US10668074B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Klaus Dugi · Dresden, DE
• Frank Himmelsbach · Mittelbiberach, DE
• Michael Mark · Biberach an der Riß, DE

Key dates

• Filing date: Aug 14, 2018
• Grant date: Jun 2, 2020
• Expiry date: Aug 14, 2038

Classification

• Technology area (CPC —): General

Abstract

The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.